Profil contributes to the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16, 2011

• LY2599506, a novel glucokinase activator (GKA) improves fasting and postprandial glucose in patients with type 2 diabetes mellitus
  Bue-Valleskey JM, Schneck KB, Sinha VP, Wondmagegnehu ET, Kapitza C, Miller JW

• Determining the renal threshold for glucose excretion: validation of a new method Polidori D, Sha S, Ghosh A, Farrell K, Rothenberg P, Heise T
  
  
• Insulin degludec: two-fold longer half-life and more consistent pharmacokinetic profile than insulin glargine Heise T, Hövelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H
  
  
• Multi-hexamer formation as the underlying basis fort the ultra-long glucose-lowering effect of insulin degludec Kurtzhals P, Heise T, Strauss HM, Bottcher SG, Granhall C, Haahr H, Jonassen I
  
  
• Ultra-long acting insulin degludec has a flat and stable glucose-lowering effect Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H
  
  
• Systematic evaluation of the influence of hyperglycemia on diastolic myocardial function Hövelmann U, Hermanski L, Nosek L, Kapitza C, Heise T, Heinemann L, Jax T
  
  
• The effect of KB003305, a liver-selective glucocorticoid receptor antagonist, on fasting plasma glucose and oral glucose tolerance after multiple oral doses in patients with diabetes type 2 Jax T, Kapitza C, Nilsson S, Breuer, O
  
  
• Prognosis of diabetes related complications by continuous glucose monitoring profiles Thomas A, Heinemann L
  
  
• Bed rest as a model for immobility-induced insulin resistance Heer M, Wnendt S, Frings-Meuthen P
  
  

Profil contributed to the American Diabetes Association´s 71th Scientific Sessions in San Diego, CA, June 24-28, 2011

• Recovery from hypoglycemic clamp in type 2 diabetes (T2DM) patients during beta-adrenergic blockade plus glucagon receptor blockade with MK-0893 Troyer MD, Hompesch M, Jax T, Pramanik B, Liu F, Morrow L, Win K, Reynders T, Liu C, Engel S, Heise T, Maliwat E, Denney W, Kelley DE, Wagner JA, Stoch A
  
  
• LY2599506, a novel glucokinase activator (GKA), improves fasting and postprandial glucose in patients with type 2 diabetes mellitus (T2DM) Bue-Valleskey J, Schneck K, Sinha VP, Wondmagegnehu E, Kapitza C, Miller JW
  
  
• The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Haahr H
  
  
• Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H
  
  
• Insulin degludec has a two-fold longer half life and a more consistent pharmacokinetic profile than insulin glargine Heise T, Hövelmann U, Nosek L, Feldmann A, Rasmussen S, Haahr H
  
  
• Multi-hexamer formation is the underlying meachanism behind the long-acting glucose-lowering effect of insulin degludec Kurtzhals P, Heise T, Strauss HM, Bottcher SG, Granhall C, Haahr H, Jonassen IB
  
  
• Prognosis of diabetes-related complications by continuous glucose monitoring profile: data of the JDRF study analyzed by the glucose-pentagon-model Thomas A, Heinemann L

Profil contributed to the Meeting of the Diabetes and Nutrition Study Group in Rome, Italy, June 30 – July 2, 2011

• High protein intake improves insulin sensitivity but exacerbates bone resorption in immobility
  Heer M, Smith SM, Frings-Meuthen P, Zwart SR, Baecker N, Biolo G

• Fourteen days of light physical workload reverse impaired glucose tolerance induced by bed rest
  Heer M, Wnendt S, Frings-Meuthen P

Profil contributed to the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, September 21-24, 2010

• A novel pH-neutral formulation of the monomeric insulin VIAject® has a faster onset of action than insulin lispro
  Nosek L, Heise T, Flacke F, Krasner A, Pichotta P, Heinemann L, Steiner S
  
  
• Accuracy of a continuous glucose monitoring System (CGMS): still room for improvement
  Heckermann S, Nosek L, Zijlstra E, Heise T
  
  
• Intensive care unit (ICU) glucose monitoring measured in plasma using mid-infrared spectroscopy
  Lim G, Calentine C, Gable J, Nosek L, Heise T
  
  

• Linagliptin, a novel DPPIV inhibitor: no need for dose adjustment in patients with renal impairment
  Graefe-Mody U, Friedrich C, Port A, Ring A, Heise T, Halabi A, Woerle HJ
  
  
• Restoration of insulin release with lixisenatide in patients with type 2 diabetes
  Becker RH, Ruus P, Liu YH, Kapitza C
  
  
• Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes: results of a phase 1b study
  Rothenberg PL, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Blake J, Wexler D, Tan Y, Smulders K, Demarest K, Sha S
  
  
• Insulin degludec: less pharmaocodynamic variability than insulin glargine under steady state conditions
  Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, Haahr H
  
  
• Once daily use of a new-generation, ultra-long-acting basal insulin with a bolus boost in insulin naïve people with type 2 diabetes: comparison with insulin glargine
  Cuddihy, T., Tack CJ, Heise T, Davidson JA, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R
  
  

Profil contributed to the American Diabetes Association´s 70th Scientific Sessions in Orlando, FL, June 25-29, 2010

• Once-Daily Use of a New Generation Ultra-Long Acting Basal Insulin with a Bolus Boost in Insulin-Naïve Subjects with Type 2 Diabetes: Comparison with Insulin Glargine
  Heise T, Tack C, Cuddihy RM, Davidson J, Gouet D, Liebl A, Bobillo ER, Mersebach H, Dykiel P, Jorde R
  
  
• Intensive Care Unit (ICU) Glucose Monitoring Measured in Plasma Using Mid-Infrared Spectroscopy
  Heise T, Nosek L, Lim G, Calentine C
  
  
• Accuracy of a Novel Continuous Glucose Monitoring System (CGMS) Using Intravenous (iv) Microdialysis
  Zijlstra E, Hartlep M, O´Connell M, Heise T, Künnecke W
  
  

• A Novel pH-Neutral Formulation of the Monomeric Insulin VIAject® Has a Faster Onset of Action Than Insulin Lispro
  Heise T, Nosek L, Flacke F, Krasner A, Pichotta P, Heinemann L, Steiner S
  
  
• Accuracy of a Continuous Glucose Monitoring System (CGMS): Still Room for Improvement
  Heckermann S, Nosek L, Zijlstra E, Heise T
  
  
• Restoration of Insulin Release with Lixisenatide in Patients with Type 2 Diabetes
  Becker RHA, Ruus P, Steinstraesser A, Kapitza C
  
  
• Phase I study of Taspoglutide Immediate Release Formulation (IRF) on Insulin Secretion in Patients (pts) with Type 2 Diabetes (T2D)
  Pellenda C, Mangold B, Schulte M, Niggli M, Kapitza C
  
  
• KB003305, a Liver-Targeted Glucocorticoid Receptor Antagonist: A First-In-Man Study To Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses in Healthy Male Volunteers
  Kapitza C, Jax T, Nilsson S, Breuer O
  
  
• The Effect of KB003305, a Liver-Targeted Glucocorticoid Receptor Antagonist, on Fasting Plasma Glucose and Oral Glucose Tolerance after Multiple Oral Doses in Patients with Diabetes Type 2
  Jax T, Kapitza C, Nilsson S, Breuer O
  
  
• Impact of Atorvastatin Treatment on Residual Beta Cell Function in Recent-Onset Type 1 Diabetes
  Kolb H, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Martin S
  
  
• BI 10773, a Sodium-Glucose Co-Transporter Inhibitor (SGLT-2), Is Safe and Efficacious Following 4-Week Treatment in Patients with Type 2
  Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, Seman L, Woerle HJ
  
  
• Safety and Tolerability of BI 10773, a Sodium-Glucose Co-Transporter (SGLT-2) Inhibitor following 8-days Treatment in Patients with Type 2 Diabetes
  Seman L, Macha S, Jones P, Marquart A, Port A, Pinnetti S, Heise T, Dugi KA
  
  
• Characterization of Metabolism Parameters Following Technosphere^® Insulin and Insulin Lispro
  Potocka E, Hovorka R, Baughman R, Klein O, Dellweg S,Umpleby M, Haworth P, Mills R, Boss AH, Richardson PC
  
  
• Canagliflozin, a Novel Inhibitor of Sodium Glucose Co-transporter 2, Improved Glucose Control in Subjects with Type 2 Diabetes and Was Well Tolerated
  Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Blake J, Wexler D, Tan Y, Smulders K, Demarest K, Rothenberg P